Autopsy report · NCT02635633

Continuous Thetaburst Stimulation for the Treatment of Refractory Epilepsy - Safety, Feasibility and Proof-of-concept

“Difficulty identifying and including eligible patients”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 1 month before it stopped.
• 7 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

University Hospital, Ghent

Sponsor type

University, hospital or other

Conditions

Epilepsies, Partial

Interventions

continuous thetaburst stimulation

Participants

7

Sites

1

Countries

Belgium

Trials that died the same way

• Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain
  “Difficulty identifying and enrolling eligible patients” (90% match in meaning)
• The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study
  “Lack of eligible patients” (80% match in meaning)
• Endothelial Protection in Convalescent COVID-19 Patients
  “Lack of the eligible patients” (80% match in meaning)
• Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions
  “Not enough eligible patients available” (77% match in meaning)
• Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques
  “Lack of eligible patients willing and able to participate” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.